NCYT
NEUTRALNovacyt Announces Notice of Results
The healthcare company has announced it will report its unaudited interim results for the first half of 2025 on 30 September 2025.
Novacyt S.A.
39.50GBX
-0.75%
Market Cap
28.13M
Volume
3
0% of avg
P/E Ratio
NaN
EPS (TTM)
Beta
0.09
Day Range
0.00p - 0.00p
52 Week Range
0.00p39.50p73.60p
39.50p
Upcoming Events
30 September 2025
Novacyt to report H1 2025 results
NCYT
NEUTRALNovacyt Appoints Singer Capital Markets as Joint Corporate Broker
The healthcare company has appointed Singer Capital Markets as a joint corporate broker, working alongside its existing broker SP Angel.
NCYT
NEUTRALNovacyt Resolves Lab 21 HSE Prosecution
The healthcare company has resolved a legal prosecution against one of its subsidiaries, with the subsidiary pleading guilty and receiving a fine.
NCYT
NEUTRALNovacyt Reports Mixed H1 2025 Trading Update
The healthcare company reports mixed H1 2025 trading, with underlying revenue growth offset by a slight statutory revenue decline. The firm remains focused on executing growth to reach profitability.
NCYT
NEUTRALNovacyt Launches New LightBench® Discover Instrument
The healthcare company has launched a new high-precision 3-in-1 instrument for genomic research labs conducting long-read sequencing.
NCYT
NEUTRALNovacyt Publishes Annual Report
The healthcare company has published its annual report for the year ended 31 December 2024.
NCYT
NEUTRALNovacyt Announces AGM Voting Details
The healthcare company provides details on the upcoming Annual General Meeting, including instructions for shareholders to vote in advance.
NCYT
NEUTRALNovacyt Announces Notice of Annual General Meeting
The healthcare company has announced the date and details for its upcoming Annual General Meeting.
NCYT
BADNovacyt Reports Widening Losses Despite Revenue Growth in FY2024 Results
The molecular diagnostics firm reported widening losses despite revenue growth, as it grapples with restructuring costs and a challenging market environment. Management aims to reach profitability through cost-cutting and new product launches.
NCYT
NEUTRALNovacyt Announces Upcoming FY 2024 Results Webinar
The healthcare company will report its audited financial results for the year ended 31 December 2024 and host an investor webinar on 30 April 2025.